Shopping Cart
- Remove All
Your shopping cart is currently empty
Duligotuzumab
🥰Excellent
Catalog No. T80604Cas No. 1314238-96-4
Alias RO-5541078, RG7597, RG 7597, MEHD-7945A, MEHD7945A
Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, suitable for studying solid tumours, head and neck cancer, and colorectal cancer.
Duligotuzumab
Duligotuzumab
🥰Excellent
Purity: 95%
Catalog No. T80604Alias RO-5541078, RG7597, RG 7597, MEHD-7945A, MEHD7945ACas No. 1314238-96-4
Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, suitable for studying solid tumours, head and neck cancer, and colorectal cancer.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $396 | In Stock | |
| 5 mg | $987 | In Stock | |
| 10 mg | $1,650 | In Stock | |
| 25 mg | $2,460 | In Stock | |
| 50 mg | $3,320 | In Stock |
Add to Cart
Add to Quotation
Bulk & Custom
Questions
View More
Select Batch
Concentration:18.734 mg/mL
Purity:95%
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, suitable for studying solid tumours, head and neck cancer, and colorectal cancer. |
| Targets&IC50 | 0E19 cells:0.1-0.5 μM, OE33 cells:0.1-0.5 μM, NCI-N87 cells:0.1-0.5 μM |
| In vitro | Methods: Duligotuzumab (0.01-25 μM) was used to treat NCI-N87, OE19, and OE33 cells, and cell viability was determined by MTT assay. Results: The IC50 values of duligotuzumab for the above three cell lines ranged from 0.1 to -0.5 μM. [1] |
| Alias | RO-5541078, RG7597, RG 7597, MEHD-7945A, MEHD7945A |
| Cas No. | 1314238-96-4 |
Storage & Solubility Information
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Sci Citations
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Duligotuzumab | purchase Duligotuzumab | Duligotuzumab cost | order Duligotuzumab | Duligotuzumab in vitro
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.